| abstract |
Disclosed is a therapeutic agent for killing or reducing the cause cells of smoldering or chronic adult T-cell leukemia (Indolent ATL), that is, HTLV-1-infected CD4 + T cells. A therapeutic agent comprising a substance that inhibits ABL1 tyrosine kinase encoded by an ABL1 gene as an active ingredient, and at least one selected from the group consisting of imatinib, nilotinib, and dasatinib One substance is an active ingredient. [Selection] Figure 1 |